AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims:

1-47 (Canceled)

48. (Currently Amended) A method for treating a human patient suffering from stroke, said method comprising administering to said patient directly at the site of said stroke a substantially pure population of ~~isolated~~ human CD34+/-, Lin- cells from umbilical cord blood (UCB) or peripheral blood, wherein the administration of said cells results in measurable stroke recovery in said patient.

49. (Currently Amended) The method of claim 48, wherein ~~the~~ said cells are isolated from UCB.

50. (Currently Amended) The method of claim 48, wherein ~~the~~ said cells are isolated from peripheral blood.

51. (Previously Presented) The method of claim 48 further comprising concurrently with or following administration of said cells administering a growth factor to said patient.

52. (Currently Amended) The method of claim 51, wherein ~~the~~ said growth factor is

selected from the group consisting of oncostatin M, FGF, neurotrophin, IGF, CNTF, EGF, TGF-beta, LIF, interleukins, PDGF, and VEGF.

53. (Previously Presented) The method of claim 48, wherein said cells are allogeneic cells.

54. (Previously Presented) The method of claim 48, wherein said cells are autologous cells.

55. (Currently Amended) The method of claim 48, wherein ~~the~~ said cells are characterized as negative for expression of CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and glycophorin A, and positive for expression of flk-1, CD45, CXCR4, and MDR.

56. (New) The method of claim 48, wherein said method comprises administering a population of cells consisting of human CD34+/-, Lin- cells.

57. (New) A method for treating a human patient suffering from stroke, said method comprising the steps of:

(a) obtaining a substantially pure population of CD34+/-, Lin- cells from umbilical cord blood (UCB) or peripheral blood using a selection element; and

(b) administering said cells to said patient directly at the site of said stroke, wherein the administration of said cells results in measurable stroke recovery in said patient.

58. (New) The method of claim 57, wherein said selection element comprises an antibody.

59. (New) The method of claim 57, wherein step (a) is performed using positive selection.

60. (New) The method of claim 57, wherein step (a) is performed using negative selection.

61. (New) The method of claim 57, wherein said cells are isolated from UCB.

62. (New) The method of claim 57, wherein said cells are isolated from peripheral blood.

63. (New) The method of claim 57 further comprising concurrently with or following administration of said cells administering a growth factor to said patient.

64. (New) The method of claim 63, wherein said growth factor is selected from the group consisting of oncostatin M, FGF, neurotrophin, IGF, CNTF, EGF, TGF-beta, LIF, interleukins, PDGF, and VEGF.

65. (New) The method of claim 57, wherein said cells are allogeneic cells.

66. (New) The method of claim 57, wherein said cells are autologous cells.

67. (New) The method of claim 57, wherein said cells are characterized as negative for expression of CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and glycophorin A, and positive for expression of flk-1, CD45, CXCR4, and MDR.

68. (New) The method of claim 57, wherein said method comprises administering a population of cells consisting of human CD34+/-, Lin- cells.